Ireland
--:--IST
Latest
Clinical Trials in Denmark / NCT07472075
Recruiting Phase 2

Melatonin Versus Placebo for Bipolar Disorder

NCT07472075 · tracked via the Priya Life Science Denmark tracker
Sponsor
Lars Vedel Kessing
Phase
Phase 2
Started
2026-05-08
Last updated
2026-05-12

Condition(s) studied

Bipolar Affective Disorder

Investigational drug(s) / intervention(s)

Melatonin →Placebo

Melatonin: Oral: Melatonin capsule 6 mg, 1 capsule/day

Placebo: Oral Placebo capsule, 1 capsule/day

Study summary

The objective with this study is to conduct a 6-month RCT comparing effects of add-on melatonin versus add-on placebo on mood stabilisation and other critical patient outcomes in patients with BD and to test whether principal effects are antimanic, antidepressant and/or prophylactic against relapse

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Bipolar disorder with diagnosis confirmed by SCAN interview * Age 18 - 70 years * The participants must be able to read and understand the participant information in their native language and consent (English and Danish) * Habile (i.e able to give informed consent) Exclusion Criteria: * Past intolerance to melatonin (allergic reactions) * Impaired renal or hepatic function (defined by GFR \<60 ml/min and/or ALAT over allowed reference value) * Women who are pregnant, breastfeeding or planning pregnancy in near future.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Mental Health Center Copenhagen, Copenhagen Affective Research Center (CADIC) Frederiksberg Denmark Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07472075 on ClinicalTrials.gov ↗ ← All trials in Denmark